The number of Coronavirus cases crosses 100,000, stocks plummet to multi-year record lows on the Black Monday of 2020, and Italy is forced into lockdown. Pretty grimm news for people around the world, investors and governments. Just when we thought things could not get any worse the World Health Organisation (WHO) labelled the Coronavirus a […]
Category Archives: Pharmaceutical and Biotechnological Stocks
Everything you need to know before investing in PAR and CUV during the coronavirus.
Are you frustrated with the market acting like a rollercoaster? If yes, then you are not alone. Many smart investors, have had enough with the media suffocating the public on the coronavirus. Many investors are now basing their entire financial decision on what the media reports. Consequently, the coronavirus fear is beating down fundamentally strong […]
Everything you need to know about iBio before investing.
IBio Inc (NYSE:IBIO) is a Texas based Bio-Pharmaceutical company which has seen a recent surge of 720% in 2020 alone. The recent Coronavirus scare has led investors to divert their capital into Bio-pharma stocks such as iBIO, due to the companies efforts in developing a vaccine to control the virus. In early February, the company announced […]
Why did Ex-NFL player Mitch Marrow call PAR’s drug life changing?
A silver lining in the current bearish decline is the opportunity to possibly enter strong stocks like Paradigm Biopharmaceuticals (ASX: PAR). PAR is one of Australia’s most talked-about biotechs of 2019 and 2020 so far. PAR strives to alleviate the suffering and cartilage degradation of Osteoarthritis patients through its repurposed drug Zilosul. Today we will […]
Why did CUV skyrocket by 22% yesterday ?
Investors are strapping themselves in as a bumpy ride could be ahead with the coronavirus panic continuing to control the markets. In times like these, fundamentally strong stocks are going for a discount. Clinuvel (ASX: CUV), based on my research, is a fundamentally strong stock. CUV delivers treatments, through their drug SCENESSE, to people suffering […]
Here’s 4 hand sanitiser stocks, besides ZNO, that you are missing out on
Coronavirus. It’s all everyone is talking about. From the media to investors to your uber driver. However, the bombardment of information, particularly from the media, is causing the coronavirus fear to become overinflated. In turn, many investors saw nothing but red in their portfolios as the fear drove down the ASX by 9.58% last week. […]
Here’s why PAR is worth watching now more than ever?
When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]
Here’s why CUV is worth holding throughout the Coronavirus panic?
It is rare to discover a sensational biotech from Australia. Why? Because when we search for quality Biotechs our eyes look to Europe. Especially, as the European countries like England, Germany, Belgium and Switzerland pride themselves on their extensive research. Just think of the most reputable biotechs in Europe such as Cambridge Antibody Technology, Micromet […]
Will PAR’s H1 2020 financials trigger a surge this week?
In my opinion, biotechnology is the most entertaining industry in the stock market. Why? Three reasons. 1) Biotech tends to be up even when the market is down. Because our ageing population continues to demand the best medicine to sustain a higher life expectancy. 2) Second, there is a range of top-quality biotechs under […]
Does CUV’s 45% plummet provide a golden opportunity for investors?
Have you heard of Clinuvel Ltd (ASX: CUV)? The skin disorder company is famous in Germany and Australia. Clinuvel captivated investors in 2019 with an impressive 150% surge, leading to their high of $45 in October. However, CUV decreased 43% since its $45 high. Today we will discuss why Clinuvel’s plummet is an opportunity, what […]
CSL up 928% in 10 years, will the exponential growth continue in 2020?
Commonwealth Serum Laboratories ASX: CSL, is one of the world’s most talked-about biotech companies. Therefore, it is no surprise that when CSL reached $321 (5/02/2020) the media attention surrounding the company exploded. Today we are discussing CSL’s financials, 2020 outlook and whether they are worth the investment in 2020. Financials Positives Investor excitement around CSL […]
Will IMU’s cancer trials cause a surge in stock price?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Imugene Ltd (ASX:IMU) has one of the most exciting stock stories in the biotech industry. Why? Because IMU strives to cure cancer, through a range of new Immuno oncology therapies. […]
Why this ASX cannabis stock is the only one worth watching in 2020?
Every cannabis stock has its story. Ecofibre (ASX: EOF) experienced an 88% YTD increase since listing at $1.70 back in March 2019. Unlike, your traditional cannabis company EOF operates under a unique business model. EOF’s cannabis footprint covers medicinal cannabis, plant-based protein and HEMP. EOF strives to use cannabis to change people’s lives. First, by […]
Has the coronavirus created a possible entry for PAR ?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of […]
PAR on the rise with a strong 6 month growth of 120%
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Paradigm Co (PAR:ASX) has been one of our top performing stocks which we’ve been closely following since we started Youth Investment Group. We first noticed Paradigm bouncing around $1.85 and saw it’s […]
After a 65% decrease is this stock a perfect buy for 2020?
Botanix Pharmaceuticals (ASX: BOT) is an Australian medicinal cannabis company. Botanix focuses on delivering treatments to fight serious skin diseases. These include acne, psoriasis, and atopic dermatitis. Botanix looks to disrupt the skincare market by harnessing the potential of cannabidiol. Existing skincare treatments produce unpleasant side effects. Thus, providing Botanix, if their novel drugs are […]
Here is why this biotech will dominate the market in 2020
Who is Clinuvel Ltd? Clinuvel Ltd (ASX: CUV), founded in 1987, is a leading biopharmaceutical Australian company. CUV specialises in delivering treatments for severe skin disorders. Clinuvel’s primary drug, SCENESSE, protects patients, whose light-sensitive skin cannot tolerate UV radiation. Patients who suffer from Erythropoietic Protoporphyria (EPP) live reclused isolated life. However, once patients receive SCENESSE […]
ASX cannabis stock plunges 90%, could this opportunity allow investors to enter the cannabis market for 2020?
ASX cannabis stocks are speculative. Australia has no clear cannabis leader. Because of the bearish storm that brought most of the industry down in 2019. Today we analyse whether Creso Pharma’s decrease provides market entry for investors? Creso Pharma (CPH) is an Australian cannabis company with operations in Israel, Australia, Colombia, Canada, and Switzerland. CPH […]
Bearish trend sees cannabis stocks plummet, how will the industry cope in 2020?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Flashback to 2018 and the cannabis industry was booming with uncontrollable excitement. Penny stocks were surging to record highs. Primarily, because Investors saw the cannabis market as a megatrend with […]
Update: Will Paradigm’s stock price surge continue into 2020?
Why all the excitement in 2019? Paradigm Biopharmaceuticals captivated investors with an impressive 300% rise over 2019. Paradigm aims to alleviate the suffering and cartilage degradation of Osteoarthritis through their repurposed drug Zilosul. PAR’s rapid stock rise was due to the company’s outstanding collection of clinical data on Zilosul. For any Biotech to achieve success, […]